Relationship between aberrant methylation of SLC22A18 gene promoter and SLC22A18 expression in glioma
10.3760/cma.j.issn.1671-8925.2011.06.003
- VernacularTitle:SLC22A18基因启动子甲基化与胶质瘤SLC22A18表达的关系
- Author:
Sheng-Hua CHU
1
;
Yan-Bin MA
;
Dong-Fu FENG
;
Hong ZHANG
;
Zhi-Qiang LI
;
Pu-Cha JIANG
Author Information
1. 上海交通大学医学院附属第三人民医院
- Keywords:
SLC22A18;
Methylation;
Glioma;
Methylation-specific PCR
- From:
Chinese Journal of Neuromedicine
2011;10(6):548-551
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between aberrant methylation of SLC22A18 gene promoter and SLC22A18 expression in human glioma. Methods Thirty patients with glioma and 10 patients with craniocerebral injury performed decompression were chosen in our study;their tissue samples were prepared. Methylation-specific PCR (MSP) was used to detect the methylation status of SLC22A18 gene promoter;and Western blotting and RT-PCR were employed to measure the protein and mRAN expressions of SLC22A18 in these tissue samples. U251 cells were cultured in vitro with demethylating agent 5-aza-2-deoxycytidine (experimental group, 2μmol/L) and common medium (control group), resepectively;the re-expression of SLC22A18 in U251 cells was measured by Western blotting and cell growth suppression induced by 5-aza-2-deoxycytidine was also observed 3, 5 and 7 d after the culture. Results The methlylation of SLC22A18 gene promoter existed in glioma tissues of 15 patients (50%) but that did not exist in the tissues of patients with craniocerebral injury. The protein and mRAN expressions of SLC22A18 in the tissue samples of these 15 patients were significantly decreased as compared with those in patients with craniocerebral injury (P<0.05);cell counting of U251 cells in the experimental group on the 5th and 7th d of culture was significantly decreased as compared with that of those in the control group (P<0.05). On the 7ht d of culture, Western blotting indicated that the protein b expression level of SLC22A18 in the experimental group was obviously higher than that in the control group. Conclusion The aberrant methylation of SLC22A18 gene promoter plays a key role in down-regulating SLC22A18 expression, and demethylation agents can restore the SLC22A18 expression and suppress the growth of U251 cells.
